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Abstract
Background: Heritable thrombophilias are assumed important etiologies for recurrent pregnancy loss. Unlike in the
Caucasian populations, protein S and protein C deficiencies, instead of Factor V Lieden and Prothrombin mutations,
are relatively common in the Han Chinese population. In this study we aimed to investigate the therapeutic effect
of low molecular weight heparin upon women with recurrent pregnancy loss and documented protein S deficiency.
Methods: During 2011–2016, 68 women with recurrent pregnancy loss (RPL) and protein S deficiency (both the free
antigen and function of protein S were reduced) were initially enrolled. All the women must have experienced at least
three recurrent miscarriages. After excluding those carrying balanced translocation, medical condition such as diabetes
mellitus, chronic hypertension, and autoimmune disorders (including systemic lupus erythematosus and anti-
phospholipid syndrome), coexisting thrombophilias other than persistent protein S deficiency (including transient low
protein S level, protein C deficiency, and antithrombin III), only 51 women with RPL and sole protein S deficiency were
enrolled. Initially they were prescribed low dose Aspirin (ASA: 100 mg/day) and unfortunately there were still
39 women ended up again with early pregnancy loss (12 livebirths were achieved though). Low-molecular-weight-
heparin (LMWH) was given for the 39 women in a dose of 1 mg/Kg every 12 h from the day when the next clinical
pregnancy was confirmed to the timing at least 24 h before delivery. The perinatal outcomes were assessed.
Results: Of 50 treatment subjects performed for the 39 women (i.e. 11 women enrolled twice for two pregnancies), 46
singletons and one twin achieved livebirths. The successful live-birth rate in the whole series was 94 % (47/50).
Nineteen livebirths delivered vaginally whereas 28 delivered by cesarean section. The cesarean delivery rate is thus 59.
57 %. Emergent deliveries occurred in 3 but no postpartum hemorrhage had been noted.
Conclusions: Our pilot study in Taiwan, an East Asian population, indicated anti-coagulation therapy is of benefit to
women with recurrent pregnancy loss who had documented sole protein S deficiency.
Trial registration: ISRCTN64574169. Retrospectively registered 29 Jun 2016.
Keywords: Anticoagulation, Protein S deficiency, Thrombophilia, Recurrent miscarriages, Low-molecular-weight-
heparin
* Correspondence: mchen_cch@yahoo.com; mingchenmd@gmail.com
†Equal contributors
2Department of Obstetrics and Gynecology, Changhua Christian Hospital,
Changhua, Taiwan
3Department of Genomic Medicine, Changhua Christian Hospital, 500
Changhua, Taiwan
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Shen et al. Thrombosis Journal  (2016) 14:44 
DOI 10.1186/s12959-016-0118-9
Background
Habitual abortion (defined as at least three recurrent
miscarriages), namely recurrent pregnancy loss (RPL), is
a condition caused by heterogeneous etiologies such as
hormonal (luteal defect), chromosomal (carriers of bal-
anced translocation), structural (Mullerian anomalies
such as didelphys, bicornuate, or septate uterus), im-
munological (anti-phospholipid antibody or aberrations
involving nature killer cells), and thrombophilia [1, 2].
Among them, heritable thrombophilias are treatable the-
oretically despite most published studies, including some
but very limited well-conducted randomized trials, in
the literature did not observe an apparent benefit by
using anticoagulants to enhance the livebirth rate in
women with RPL [3–9].
Heritable thrombophilias ever reported with clinical
significance include protein S deficiency, protein C defi-
ciency, anti-thrombin III deficiency, Factor V Leiden
mutation, and prothrombin mutation, however, there are
ethnic differences: The most common heritable throm-
bophilias in the Caucasian populations are Factor V
Leiden mutation and prothrombin mutation whereas
in Taiwan, protein S, protein C, and antithrombin III
deficiencies are the most common [10–14]. Despite
most published reports in the literature failed to ob-
serve a beneficial effect of anti-coagulants to enhance
the livebirth rates in women with RPL, it may be inappro-
priate to extrapolate those results, mainly based on other
ethnic groups, into an East Asian population (Taiwan is a
multi-ethnic group country with a predominance of Han
Chinese). According to our previous studies, the most
common heritable thrombophilias in the thromboembolic
patients in Taiwan are protein S and protein C deficiencies
[13, 14]. Meanwhile, the selection criteria and treatment
protocol varied across different studies and thus we
should be cautious when reading reviews based upon
meta-analysis [3–5, 15].
We are keen to explore if there is any role of using an-
ticoagulants in this group of patients in Taiwan. In order
to better define the enrollment criteria, those with other
confounding factors such as anti-phospholipid antibody
syndrome, underlying medical conditions including
autoimmune diseases, diabetes mellitus, chronic hyper-
tension, and previous history of thromboembolism are
excluded. Only nulliparous women with protein S defi-
ciency and suffered from RPL are enrolled in this pilot
study. We intended to include women with in whom
protein S deficiency is the only attributable etiology, and
from another point of view, to include women with pro-
tein S deficiency who were otherwise healthy (that is,
without previous thromboembolic events) until adult life
except suffering from RPL. In addition, in order to sim-
plify and better understand the actual effect of anti-
coagulants in the enrolled cases, we only included those
receiving low-molecular-weight-heparin as the sole ther-
apy. The livebirth rate is the primary outcome we aimed
to observe in this historical cohort. Attributable causes
of the failed cases, if any, will be assessed by examina-




During 2011–2016, women suffered from at least three
recurrent miscarriages who came to our clinic received a
series of investigation including karyotyping, thrombo-
philia profile (antithrombin III, protein C, Protein S
levels), and immune profile (lupus anti-coagulant to ex-
plore if she has anti-phospholipid antibody syndrome).
Only those women with sole protein S deficiency, and
naturally conceived, were enrolled. They were prescribed
low dose Aspirin (ASA, 100 mg per day) when another
new pregnancy was achieved and in those ended up
again with early pregnancy loss (less than 12 complete
weeks of gestation), these patients were enrolled in this
cohort and would be given daily anti-coagulant treat-
ment in the injection starting from when next pregnancy
is established. It is noteworthy that since the level of
protein S may decrease physiologically during pregnancy
due to the estrogen effect, only those with persistent low
protein S level in the non-gestational period (we enrolled
only those with low levels in both protein S function
and free protein S antigen (Ag)), were included. Assays
adopted for protein S measurement used the functional
assay by clotting based kits (the reference ranges: protein
S function 63.5~149 %; free protein S antigen:
54.7~123.7 %) according to the method reported by Mo-
raes and colleagues in 2000 [16]. Women with other her-
itable thromobophilias (Protein C and antithrombin III
deficiency), immune problems (such as systemic lupus
erythematosus, anti-phospholipid antibody syndrome),
other pre-conceptional underlying medical conditions
(such as diabetes mellitus and chronic hypertension), or
carrying balanced translocation, were excluded. The in-
stitutional review board (IRB) of Changhua Christian
Hospital had approved the study (CCH-IRB-151209).
Clinical management protocol
Low-molecular-weight-heparin (enoxaparin) was given
in a dose of 1 mg/Kg every 12 h from the day being en-
rolled to the timing a few days (at least 24 h) before de-
livery. Standard antenatal care was unaffected otherwise
and the perinatal outcome was assessed. The patients re-
ceived both the antenatal care from two of the coauthors
(M Chen, an obstetrician who specializes in high-risk
pregnancy, and MC Shen, a hematologist who specializes
in thrombosis and hemostasis). In order to avoid the risk
of postpartum hemorrhage due to emergent deliveries,
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which often occurs unexpectedly, the patients were ei-
ther arranged for induction of labor if she chose to de-
liver vaginally, or scheduled cesarean section if there are
obstetric indications or by their autonomous choice to
choose elective cesareans. The anticoagulants were
ought to be stopped at least 24 h before delivery in the
ideal situation. The risk of postpartum hemorrhage as
well as other side effects that may occur because of this
treatment protocol were discussed and explained in
great details to these patients and the informed consents
were obtained. The blood coagulation profiles such as
prothrombin time (PT), activated partial thromboplastin
time (aPTT), or other assays to assess the status of the
molecules involving the coagulation cascade were not
regularly monitored. The livebirth rate is the primary
outcome indicator. Secondary outcome indicators are
also recorded for the obstetric complications such as
premature births, low birth weight, and pre-eclampsia.
The whole investigation period reported in this historical
control cohort study ended at 22, May, 2016.
Results
A total of 68 patients with at least three recurrent mis-
carriages and having protein S deficiency (both the free
antigen and the function of protein S) went to our
clinics. In these 68 patients, 17 of them were further fil-
tered out because these patients were found with herit-
able thromobophilias other than protein S deficiency
(protein C deficiency (n = 1), antithrombin III (n = 1),
immune problems (e.g., systemic lupus erythematosus
(n = 2), anti-phospholipid antibody syndrome (n = 1)), or
with other underlying medical conditions (e.g., diabetes
mellitus (n = 1) and chronic hypertension (n = 1)), or car-
rying balanced translocation (n = 1). Another 9 women
who only had transient low level of protein S during
pregnancy were also excluded. Therefore, 51 women en-
tered the cohort initially (12 of them enjoyed livebirths
simply by being given low dose Aspirin in a dose with
100 mg per day). Of the remaining 39 women, 11 had
two pregnancies being enrolled. Consequently, 50 treat-
ment subjects were performed for the 39 women and 47
livebirths were achieved (Fig. 1). Only 3 pregnancies
failed, two of which were later proved to be an aneu-
ploidy pregnancy (trisomy 22 and monosomy X respect-
ively) and one was ectopic pregnancy ended with tubal
abortion. Of the 11 women with two pregnancies en-
rolled, 10 had successful two livebirths and one had one
livebirth with one abortion due to trisomy 22. In 47 suc-
cessful livebirths, 48 live babies were born (because there
were one twin pregnancy), 19 of them delivered vaginally
(40.43 %), and 28 of them delivered by cesarean section
(59.57 %). Notably only 4 of the cesarean group
demanded elective cesarean section due to the concern
about the risk of natural births, and all the remaining 24
out of the 28 women in the cesarean group had obstetric
indications. The indications include previous uterine
surgery (n = 5, two are both repeated sections and en-
tered the group twice and the first cesareans were elect-
ive), placenta previa (n = 2), prolonged labor (n = 2), fetal
malpresentation (n = 6, one case is twin pregnancy with
one fetal malpresentation), non-reassuring fetal heart
rate tracings (n = 8), and severe pre-eclampsia (n = 1).
All the successful live babies were born after gestational
age (GA) 28 weeks (Table 1), with the patient numbers
(percentage) delivered at GA 36 weeks or greater, be-
tween GA 32 and 35+6 weeks, between GA 28 and 31+6
weeks and less than 28 weeks were 33 (70.21 %), 12
(25.23 %), 2 (4.26 %), and 0 (0 %). The distribution of
the percentiles (calculated by Hadlock chart) regarding
birth body weights of these babies was 27.08 % (n = 13, <
10th percentile, “small for gestational age (SGA)” by def-
inition), 41.67 % (n = 20, 10th–25th percentile), 22.92 %
(n = 11, 25th–50th percentile), and 8.33 % (n = 4, > 50th
percentile) (Table 2). Nine of the babies born with SGA
were in the cesarean section group (exactly those whose
indications for cesareans were non-reassuring fetal heart
rate tracings (n = 8) and severe-preeclampsia (n = 1)).
Only 3 of the entire cohort delivered emergently (two
vaginal births and one cesarean birth) and no postpar-
tum hemorrhage occurred. Pathological examination of
the placentae belonging to the SGA babies all showed
gross hypoplasia and histological vascular lesions.
In summary, the rate of successful livebirth was thus
94 % (47/50). If by comparing to their historical cohort
(the livebirth rate before being enrolled into the treatment
group is theoretically zero) themselves, the benefit to this
group of patients is clear (p = 0 by Fisher’s exact test).
Discussion
Recurrent pregnancy loss (RPL), or recurrent miscar-
riages, is a serious problem in women’s health. It affects
1–2 % of women of reproductive age if 3 or more first
trimester pregnancy losses (less than 12 complete ges-
tational weeks) and 5 % of women of reproductive age
if 2 or more first trimester pregnancy losses (less than
12 complete gestational weeks) [7]. The causes of RPL
are varying and complicated. Etiologies that had been
reported included structural (e.g., mullerian anomalies),
hormonal (e.g., luteal defect), chromosomal (e.g., bal-
anced translocation carriers), immune-related (e.g.,
anti-phospholipid antibody syndrome), thrombophilias
(e.g., factor V Lieden mutations and prothrombin mu-
tations in the caucasian populations), and others. Strat-
egies to combat these putative causative factors were
therefore developed, with varying efficacies [17, 18]. For
example, some advocated anti-coagulation therapy
(such as aspirin or low-molecular-weight-heparin) is ef-
fective in improving the pregnancy outcome in women
Shen et al. Thrombosis Journal  (2016) 14:44 Page 3 of 7
Fig. 1 Patient summary and treatment flowchart
Table 1 Summary of the gestational age (GA) at delivery and
mode of delivery of the 47 livebirths
% (= n/47)
GA at delivery
≥ 36 weeks 70.2 (33/47)
32–35+6 weeks 25.23 (12/47)
28–31+6 weeks 4.26 (2/47)
< 28 weeks 0 (0/47)
Mode of delivery
Normal spontaneous delivery 40.43 (19/47)
Cesarean section 59.57 (28/47)
Table 2 Percentile distributions of the birth body weight of the
48 live-birth babies
Percentile of birth body weight (Hadlock) % (= n/48)
SGA (<10th percentile) 27.08 (13/48)
10th–25th percentile 41.67 (20/48)
25th–50th percentile 22.92 (11/48)
>50th percentile 8.33 (4/48)
SGA small for gestational age
Shen et al. Thrombosis Journal  (2016) 14:44 Page 4 of 7
suffered from anti-phospholipid antibody syndrome and
RPL but the results were inconsistent among different tri-
als [6, 19–21]. Most of the recently conducted randomized
trials failed to show significant benefit of anti-coagulation
therapy (either aspirin or low molecular weight heparin
alone or if both were combined) to improve the livebirth
rates in women with RPL [6, 7, 15]. However, these well-
conducted trials actually did not well characterize the
underlying possible causative factors in their study sub-
jects, the subgroups due to different etiologies were
pooled and no specific analyses were conducted separately
on each subgroup.
There are at least three randomized trials conducted
in earlier times dealing with women with RPL and a
concomitant heritable thrombophilia and the results
were varying. In 2004, the French group published their
result of the randomized trial to compare low-
molecular-weight heparin (LMWH) versus aspirin (ASA)
and reported that LMWH was superior to ASA regard-
ing the livebirth rates. In 2008, the Jordan group re-
ported a similar beneficial effect of anticoagulant
therapy (LMWH versus placebo, please refer to Qubian
et al., 2008 [22]). However, the Canadian group reported
there seemed no benefit to the livebirth rates when com-
paring LMWH plus ASA and ASA alone in 2009 (the
HepASA Trial, please refer to Laskin et al., 2009 [23]).
Tan and colleagues therefore conducted a meta-analysis
and concluded that no obvious benefit can be attributed
to the anti-coagulation therapy regarding the improve-
ment of livebirth rates in women with RPL and a herit-
able thrombophilia [5]. However, the mixture of those
three randomized trials is too arbitrary to exclude the
possibility of real benefit in this group of women since
the three randomized trails had different inclusion cri-
teria and even different therapeutic regimens.
It is noteworthy that there are some recently well-
conducted randomized trials being published and all of
these trials failed to demonstrate the benefit of anti-
coagulant therapy in women with RPL (but not aiming
solely at women with heritable thrombophilias). The
Netherland study published in NEJM 2010 did included
some women with heritable thrombophilas (even in-
cluded protein S deficiency) but the authors also admit-
ted the study lacked the power to study the effect in the
subgroups of the study population [6]. The Scottish
Pregnancy Intervention study (SPIN) also included some
women with heritable thrombophilia but admitted their
result did not exclude the possible benefit in women
with a particular thrombophilia disorder as well [7]. A
recent multi-center with minimized randomization
scheme conduced in Germany and Austria actually ex-
cluded the women with constitutional thrombophilia
disorders and therefore the trial result is of no reference
value to our study [15].
In our study, it is obvious LMWH is beneficial to the
livebirth rate in women suffered from RPL with docu-
mented sole protein S deficiency (94 versus 0 % by his-
torical control). Particularly, 2 of the 11 women treated
twice had initially decided not being enrolled into the
treatment group receiving anticoagulants after one suc-
cessful birth and got pregnant again and both of them
suffered from spontaneous abortion (the karyotyping re-
sults of the abortion were both normal), and thereby
they entered the study for the second time when again
getting pregnant and successful livebirths ensued. Such
experience strengthened the justification of this study.
However, it seems LMWH was unable to prevent other
obstetric complications such as placental insufficiency
and therefore intrauterine growth restriction (IUGR) are
common in our cohort. Among 48 live born babies,
Nearly 70 % of them were born with birth weight less
than 25th percentile (68.75 %; n = 33), and the percent-
age of small for gestational age (SGA) was 27.08 %
(n = 13). Among the babies born with SGA, five infants
were born before 36 weeks of GA, including one case of
severe pre-eclampsia, one case of oligohydroamnios, and
all of them demonstrated non-reassuring fetal heart rate
tracings during intrapartum. The result was compatible
with the prior reports [24], showed a link between throm-
bophilias and fetal growth restriction (odds ratio (OR)
10.2; 95 % confidence interval (CI) 1.1–91.0) by meta-
analysis. However, available evidences in the literature do
not support the prophylactic use of anticoagulants can
prevent obstetric complications, including preeclampsia,
fetal growth restriction, or abruption in women with any
form of inherited thrombophilias [25], despite it may of be
benefit in women with recurrent implantation failures
when receiving in vitro fertilization [26]. It is still under
debate if thrombophilias truly associated, or simply it is
only by chance a coincidence, with the placental insuffi-
ciency [27]. Further investigations and surveys were
required to establish causality. Hence, in addition to anti-
coagulation therapy, frequent fetal surveillance is neces-
sary for pregnant women with thrombophilia to prevent
adverse neonatal outcomes. The American Congress of
Obstetricians and Gynecologists (ACOG) did not suggest
special management in thrombophilia patients in the ab-
sence of obstetric complications such as preeclampsia,
abruption or IUGR. Weekly fetal assessment with non-
stress test beginning at ≥36 weeks of gestation and deliv-
ery at 39 weeks of gestation is still the recommended
standard of care when managing these patients [28].
We admit the evidence level of historical control is
much lower than prospective randomized control trials.
Many inherent defects underlying the historical control
study hampered its use. The most frequently cited de-
fects of this historical control conducted by patients as
their own controls included different diagnostic criteria,
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differences in the concomitant standard of care, and
missing records across different times along the time
period (especially if the time spans very long such as 10
or 20 years). However, the credibility of historical con-
trol study may be better if there is a large treatment ef-
fect, or it is very difficult to bias outcome assessment, or
it follows the pair availability design (proposed by Baker
and Lindeman in 1994) [29–32].
Conclusion
In this study, a strikingly high 94 % successful livebirth
rate, straight-forward outcome indicators (livebirth rate
and pregnancy complications), and the short time period
(within 5 years), all indicated that our result is of better
power, despite the limitations of historical control dis-
cussed above, to convince us that such intervention did
benefit this group of patients in Taiwan. Our study
clearly demonstrated a potential benefit of daily anti-
coagulation therapy in women suffered from RPL and
had documented sole protein S deficiency. Future pro-
spective randomized studies are needed to further prove
its efficacy.
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